隆華科技(300263.SZ):公司產品包括全系列交流伺服電機、交流伺服驅動器、PLC、運動控制器等工業自動化產品
格隆匯4月1日丨隆華科技(300263.SZ)在投資者互動平臺表示,公司通過廈門仁達隆華股權投資基金合夥企業(有限合夥)持有超同步股份有限公司14.84%的股權。超同步股份有限公司專注於智能製造領域,提供伺服電機、力矩電機、電主軸等核心部件及專業的自動化伺服控制解決方案。公司產品包括全系列交流伺服電機、交流伺服驅動器、PLC、運動控制器等工業自動化產品,力矩電機、電主軸、直驅轉檯等核心功能部件,五軸立式加工中心等高端智能裝備。核心技術達到國際先進水平,關鍵產品可替代進口同類產品,廣泛應用於工業母機、工業機器人、工業自動化等領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.